Recuperação De área Degradada No Domínio Floresta Estacional Semidecidual Sob Diferentes Tratamentos

It was aimed to evaluate three treatments for forest restoration in an area with periodic elevation of the groundwater, in the Corredor de Biodiversidade Santa Maria, located between the cities of Santa Teresinha de Itaipu and São Miguel do Iguaçu, in Paraná state. The treatments were: control, green manure and soil solarization. It was performed a monthly monitoring of mortality and development of 12 tree native species of the region and the persistence of two invasive species present in the area, Megathyrsus maximus (coloniao grass) and Cyperus rotundus (coco grass). Furthermore, it was evaluated the changes introduced in the soil by three soil samples during the experiment. After over a year of assessment, the treatments showed no statistically significant differences on the evaluations. The mortality was more pronounced in January (12.08%), with a higher percentage for Cabralea canjerana (canjarana) and lower for Luehea divaricata (açoita-cavalo). About the seedlings development, growth was higher for: Sapium glandulatum (leiteiro-do-banhado), Croton urucurana (sangra-d’água) and Luehea divaricata, with monthly increases in diameter of 3.66 mm to 4.12 mm, and height of 12.39 cm to 17.02 cm. Regarding the dry mass of ‘colonião’ grass and coco grass (nutsedge) in all treatments, the highest values were found in January (94.14 g m-2) and February (132.76 g m-2), remaining low throughout the experiment. Through soil analyzes, it was observed that treatments showed no significant differences, however, the physical and chemical changes in the soil were sensitive to the invasive species management, which may lead to new modifications during the growth of seedlings. © 2016, Universidade Federal de Santa Maria. All rights reserved.26369971

NEOTROPICAL XENARTHRANS: a data set of occurrence of xenarthran species in the Neotropics

Xenarthrans – anteaters, sloths, and armadillos – have essential functions for ecosystem maintenance, such as insect control and nutrient cycling, playing key roles as ecosystem engineers. Because of habitat loss and fragmentation, hunting pressure, and conflicts with 24 domestic dogs, these species have been threatened locally, regionally, or even across their full distribution ranges. The Neotropics harbor 21 species of armadillos, ten anteaters, and six sloths. Our dataset includes the families Chlamyphoridae (13), Dasypodidae (7), Myrmecophagidae (3), Bradypodidae (4), and Megalonychidae (2). We have no occurrence data on Dasypus pilosus (Dasypodidae). Regarding Cyclopedidae, until recently, only one species was recognized, but new genetic studies have revealed that the group is represented by seven species. In this data-paper, we compiled a total of 42,528 records of 31 species, represented by occurrence and quantitative data, totaling 24,847 unique georeferenced records. The geographic range is from the south of the USA, Mexico, and Caribbean countries at the northern portion of the Neotropics, to its austral distribution in Argentina, Paraguay, Chile, and Uruguay. Regarding anteaters, Myrmecophaga tridactyla has the most records (n=5,941), and Cyclopes sp. has the fewest (n=240). The armadillo species with the most data is Dasypus novemcinctus (n=11,588), and the least recorded for Calyptophractus retusus (n=33). With regards to sloth species, Bradypus variegatus has the most records (n=962), and Bradypus pygmaeus has the fewest (n=12). Our main objective with Neotropical Xenarthrans is to make occurrence and quantitative data available to facilitate more ecological research, particularly if we integrate the xenarthran data with other datasets of Neotropical Series which will become available very soon (i.e. Neotropical Carnivores, Neotropical Invasive Mammals, and Neotropical Hunters and Dogs). Therefore, studies on trophic cascades, hunting pressure, habitat loss, fragmentation effects, species invasion, and climate change effects will be possible with the Neotropical Xenarthrans dataset

Non-volant mammals of Carlos Botelho State Park, Paranapiacaba Forest Continuum

A Mata Atlântica é o bioma melhor conhecido em relação à mastofauna no Brasil, contudo ainda assim apresenta uma série de lacunas de conhecimento sobre a persistência e distribuição de espécies, o que representa um risco adicional à conservação de mamíferos. Neste trabalho, através da coleta de dados por diferentes métodos - armadilhas fotográficas, censos diurnos, registro de vestígios, armadilhas de queda e captura viva - ao longo de oito anos (2004-2012), foi realizado o inventário da mastofauna não voadora do Parque Estadual Carlos Botelho (SP). No total foram registradas 53 espécies, sendo 12 espécies ameaçadas regionalmente e uma exótica (Lepus europaeus), com a presença da maioria dos mamíferos esperados para o Continuum Florestal da Serra do Paranapiacaba. A comunidade de mamíferos não voadores quase completa, e a presença de espécies ameaçadas reforçam o papel desta área protegida para a conservação de mamíferos na Mata Atlântica. Embora, a extinção local de uma espécie, Tayassu pecari, alerte para a necessidade de medidas efetivas de proteção.The Atlantic Forest is one of the most studied Brazilian biomes in relation to its mammalian fauna. However, there is still a series of gaps of knowledge about the distribution and persistence of some of these species which prevents taking adequate conservation measures to better protect the mammals. In order to make the inventory of the non-volant mammalian fauna of the Carlos Botelho State Park (SP), we compiled data of camera trapping, diurnal census, track records, pitfall and live trapping collected over 8 years (2004-2012). We registered a total of 53 species, of which 12 are regionally threatened and one is an exotic species (Lepus europaeus), including the presence of most mammal species expected for the Paranapiacaba Forest Continuum. The high non-volant mammals species richness allied to the presence of threatened species, strengthen the role of this protected area for mammal conservation in the Atlantic Forest. Although, the local extinction of one species, Tayassu pecari, alert to the need for effective measures of protection

Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry

Aim: The SAMe-TT2R2 score helps identify patients with atrial fibrillation (AF) likely to have poor anticoagulation control during anticoagulation with vitamin K antagonists (VKA) and those with scores >2 might be better managed with a target-specific oral anticoagulant (NOAC). We hypothesized that in clinical practice, VKAs may be prescribed less frequently to patients with AF and SAMe-TT2R2 scores >2 than to patients with lower scores. Methods and results: We analyzed the Phase III dataset of the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF), a large, global, prospective global registry of patients with newly diagnosed AF and ≥1 stroke risk factor. We compared baseline clinical characteristics and antithrombotic prescriptions to determine the probability of the VKA prescription among anticoagulated patients with the baseline SAMe-TT2R2 score >2 and ≤ 2. Among 17,465 anticoagulated patients with AF, 4,828 (27.6%) patients were prescribed VKA and 12,637 (72.4%) patients an NOAC: 11,884 (68.0%) patients had SAMe-TT2R2 scores 0-2 and 5,581 (32.0%) patients had scores >2. The proportion of patients prescribed VKA was 28.0% among patients with SAMe-TT2R2 scores >2 and 27.5% in those with scores ≤2. Conclusions: The lack of a clear association between the SAMe-TT2R2 score and anticoagulant selection may be attributed to the relative efficacy and safety profiles between NOACs and VKAs as well as to the absence of trial evidence that an SAMe-TT2R2-guided strategy for the selection of the type of anticoagulation in NVAF patients has an impact on clinical outcomes of efficacy and safety. The latter hypothesis is currently being tested in a randomized controlled trial. Clinical trial registration: URL: https://www.clinicaltrials.gov//Unique identifier: NCT01937377, NCT01468701, and NCT01671007. © 2020 Hellenic Society of Cardiolog

Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry

Aim: The SAMe-TT2R2 score helps identify patients with atrial fibrillation (AF) likely to have poor anticoagulation control during anticoagulation with vitamin K antagonists (VKA) and those with scores >2 might be better managed with a target-specific oral anticoagulant (NOAC). We hypothesized that in clinical practice, VKAs may be prescribed less frequently to patients with AF and SAMe-TT2R2 scores >2 than to patients with lower scores. Methods and results: We analyzed the Phase III dataset of the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF), a large, global, prospective global registry of patients with newly diagnosed AF and 651 stroke risk factor. We compared baseline clinical characteristics and antithrombotic prescriptions to determine the probability of the VKA prescription among anticoagulated patients with the baseline SAMe-TT2R2 score >2 and 64 2. Among 17,465 anticoagulated patients with AF, 4,828 (27.6%) patients were prescribed VKA and 12,637 (72.4%) patients an NOAC: 11,884 (68.0%) patients had SAMe-TT2R2 scores 0-2 and 5,581 (32.0%) patients had scores >2. The proportion of patients prescribed VKA was 28.0% among patients with SAMe-TT2R2 scores >2 and 27.5% in those with scores 642. Conclusions: The lack of a clear association between the SAMe-TT2R2 score and anticoagulant selection may be attributed to the relative efficacy and safety profiles between NOACs and VKAs as well as to the absence of trial evidence that an SAMe-TT2R2-guided strategy for the selection of the type of anticoagulation in NVAF patients has an impact on clinical outcomes of efficacy and safety. The latter hypothesis is currently being tested in a randomized controlled trial. Clinical trial registration: URL: https://www.clinicaltrials.gov//Unique identifier: NCT01937377, NCT01468701, and NCT01671007